Loek A W de Jong

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 12

Top Topics

Radiation Therapy

Cross Sectional

Locally Advanced

Top Venues

Cancer chemotherapy and pharmacology

British journal of clinical pharmacology

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Loek A W de Jong, Marie Lambert, Nielka P van Erp, Lukas de Vries, Etienne Chatelut, Petronella B Ottevanger
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer chemotherapy and pharmacology 91 (3) (2023)
Jeffrey Strik, Loek A W de Jong, Joost Sijm, Ingrid M E Desar, Nielka P van Erp
Effect of aprepitant on etoposide pharmacokinetics in patients with testicular cancer: a pharmacokinetic study to determine the absence of a clinically relevant interaction. Clinical pharmacology and therapeutics (2023)
Eline L Giraud, Loek A W de Jong, Erik van den Hombergh, Suzanne E J Kaal, Nielka P van Erp, Ingrid M E Desar
Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant? Cancers 15 (11) (2023)
Loek A W de Jong, Marie Lambert, Nielka P van Erp, Lukas de Vries, Etienne Chatelut, Petronella B Ottevanger
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer chemotherapy and pharmacology 91 (3) (2023)
Loek A W de Jong, Marie Lambert, Nielka P van Erp, Lukas de Vries, Etienne Chatelut, Petronella B Ottevanger
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer chemotherapy and pharmacology 91 (3) (2023)
Loek A W de Jong, Marie Lambert, Nielka P van Erp, Lukas de Vries, Etienne Chatelut, Petronella B Ottevanger
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer chemotherapy and pharmacology (2023)
Loek A W de Jong, Marie Lambert, Nielka P van Erp, Lukas de Vries, Etienne Chatelut, Petronella B Ottevanger
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer chemotherapy and pharmacology 91 (3) (2023)
Loek A W de Jong, Nielka P van Erp, Lana Bijelic
Pressurized Intraperitoneal Aerosol Chemotherapy: The Road from Promise to Proof. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (7) (2021)
Loek A W de Jong, Fortuné M K Elekonawo, Marie Lambert, Jan Marie de Gooyer, Henk M W Verheul, David M Burger, Johannes H W de Wilt, Etienne Chatelut, Rob Ter Heine, Philip R de Reuver, Andre J A Bremers, Nielka P van Erp
Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study. Cancer chemotherapy and pharmacology 86 (1) (2020)
Loek A W de Jong, Paul D van der Linden, Monique M B Roukens, Ewoudt M W van de Garde, Alike W van der Velden, Stephanie Natsch, null null
Consecutive antibiotic use in the outpatient setting: an extensive, longitudinal descriptive analysis of antibiotic dispensing data in the Netherlands. BMC infectious diseases 19 (1) (2019)
Loek A W de Jong, Nielka P van Erp
Reply to 'Hyperthermic intraperitoneal chemotherapy with oxaliplatin-Still not standard of care for patients with colorectal peritoneal metastases' by Julianov and Saroglu. British journal of clinical pharmacology 85 (8) (2019)
Loek A W de Jong, Fortuné M K Elekonawo, Philip R de Reuver, Andre J A Bremers, Johannes H W de Wilt, Frank G A Jansman, Rob Ter Heine, Nielka P van Erp
Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure. British journal of clinical pharmacology 85 (1) (2018)